Development

In vivo CRISPR posts its first Phase 3 success

development2026-04-27

Claim

Intellia Therapeutics announced the first Phase 3 success for an in vivo CRISPR treatment that edits a disease-causing gene, while runners broke the sub-two-hour marathon barrier in London in next-generation shoes.

Reported metric: Phase 3

Reporting date: 2026-04-27 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to April 27, 2026 (theinnermostloop.substack.com)

Knowledge graphopen in browser →

Reported in

Welcome to April 27, 2026

Evidence for

Biology engineered past the constraints of life

Supersedes

The first gene therapy for genetic hearing loss is approved in 61 days

Referenced by

Welcome to April 27, 2026

Cite or correct this record

Citation formatCitation text

In vivo CRISPR posts its first Phase 3 success
Innermost Loop KB — secondary record
Reporting date: 2026-04-27
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-04-27-first-phase-3-success-for-in-vivo-crispr
Claim: Intellia Therapeutics announced the first Phase 3 success for an in vivo CRISPR treatment that edits a disease-causing gene, while runners broke the sub-two-hour marathon barrier in London in next-generation shoes.
Attributed sources:
- Welcome to April 27, 2026 — https://theinnermostloop.substack.com/p/welcome-to-april-27-2026
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.